Birdwatch Note
2023-05-31 23:41:34 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Although the Europena Medical Agency Pharmacovigilance Risk Assessment Committee has recommended that heavy menstrual bleeding should be added as a side effect of the Comirnaty and Spikevax vaccines, it continues to recommend their use during pregnancy. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022
Written by 8634CE147E9A2EC095C53D83C84BC99DC5C7B4394DCD5F4F964A4462D3700A3C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1663994244376190978
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1664054542269550592
- noteId - 1664054542269550592
- participantId -
- noteAuthorParticipantId - 8634CE147E9A2EC095C53D83C84BC99DC5C7B4394DCD5F4F964A4462D3700A3C Participant Details
- createdAtMillis - 1685576494174
- tweetId - 1663994244376190978
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Although the Europena Medical Agency Pharmacovigilance Risk Assessment Committee has recommended that heavy menstrual bleeding should be added as a side effect of the Comirnaty and Spikevax vaccines, it continues to recommend their use during pregnancy. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-05-31 23:41:34 UTC (1685576494174) |
1969-12-31 23:59:59 UTC (-1) |
2023-06-01 02:11:43 UTC (1685585503373) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-05-31 19:30:41 -0500 | Rating Details | |
| 2023-05-31 19:26:00 -0500 | Rating Details | |
| 2023-05-31 19:22:34 -0500 | Rating Details | |
| 2023-05-31 19:20:51 -0500 | Rating Details | |
| 2023-05-31 19:19:04 -0500 | Rating Details | |
| 2023-05-31 19:17:34 -0500 | Rating Details | |
| 2023-05-31 19:17:32 -0500 | Rating Details | |
| 2023-05-31 18:57:00 -0500 | Rating Details | |
| 2023-05-31 18:47:36 -0500 | Rating Details | |
| 2023-05-31 18:46:02 -0500 | Rating Details | |
| 2023-05-31 18:45:09 -0500 | Rating Details | |
| 2023-06-01 19:15:18 -0500 | Rating Details | |
| 2023-06-01 17:19:51 -0500 | Rating Details | |
| 2023-06-01 17:19:48 -0500 | Rating Details | |
| 2023-06-01 17:17:47 -0500 | Rating Details | |
| 2023-06-01 17:15:31 -0500 | Rating Details | |
| 2023-06-01 17:05:56 -0500 | Rating Details | |
| 2023-06-01 15:57:03 -0500 | Rating Details | |
| 2023-06-01 14:20:45 -0500 | Rating Details | |
| 2023-06-01 14:07:15 -0500 | Rating Details | |
| 2023-06-01 14:01:26 -0500 | Rating Details | |
| 2023-06-01 11:59:11 -0500 | Rating Details | |
| 2023-06-01 10:42:57 -0500 | Rating Details | |
| 2023-06-01 10:02:43 -0500 | Rating Details | |
| 2023-06-01 09:47:58 -0500 | Rating Details | |
| 2023-06-01 09:06:38 -0500 | Rating Details | |
| 2023-06-01 08:52:57 -0500 | Rating Details | |
| 2023-06-01 08:10:05 -0500 | Rating Details | |
| 2023-06-01 07:52:28 -0500 | Rating Details | |
| 2023-06-01 07:36:42 -0500 | Rating Details | |
| 2023-06-01 07:19:46 -0500 | Rating Details | |
| 2023-06-01 07:13:37 -0500 | Rating Details | |
| 2023-06-01 07:07:41 -0500 | Rating Details | |
| 2023-06-01 07:02:08 -0500 | Rating Details | |
| 2023-06-01 07:01:44 -0500 | Rating Details | |
| 2023-06-01 06:55:50 -0500 | Rating Details | |
| 2023-06-01 06:47:19 -0500 | Rating Details | |
| 2023-06-01 06:09:45 -0500 | Rating Details | |
| 2023-06-01 05:56:11 -0500 | Rating Details | |
| 2023-06-01 05:54:40 -0500 | Rating Details | |
| 2023-06-01 04:56:02 -0500 | Rating Details | |
| 2023-06-01 04:19:19 -0500 | Rating Details | |
| 2023-06-01 03:38:24 -0500 | Rating Details | |
| 2023-06-01 03:08:38 -0500 | Rating Details | |
| 2023-06-01 03:05:12 -0500 | Rating Details | |
| 2023-06-01 02:04:59 -0500 | Rating Details | |
| 2023-06-01 01:51:06 -0500 | Rating Details | |
| 2023-06-01 01:45:39 -0500 | Rating Details | |
| 2023-06-01 01:32:41 -0500 | Rating Details | |
| 2023-06-01 01:30:26 -0500 | Rating Details | |
| 2023-06-01 01:23:52 -0500 | Rating Details | |
| 2023-06-01 01:16:51 -0500 | Rating Details | |
| 2023-06-01 00:34:57 -0500 | Rating Details | |
| 2023-06-01 00:30:47 -0500 | Rating Details | |
| 2023-06-01 00:22:57 -0500 | Rating Details | |
| 2023-06-01 00:13:48 -0500 | Rating Details | |
| 2023-06-01 00:08:09 -0500 | Rating Details | |
| 2023-05-31 23:49:53 -0500 | Rating Details | |
| 2023-05-31 23:20:26 -0500 | Rating Details | |
| 2023-05-31 22:33:47 -0500 | Rating Details | |
| 2023-05-31 22:31:17 -0500 | Rating Details | |
| 2023-05-31 22:19:31 -0500 | Rating Details | |
| 2023-05-31 22:18:32 -0500 | Rating Details | |
| 2023-05-31 22:11:34 -0500 | Rating Details | |
| 2023-05-31 22:05:01 -0500 | Rating Details | |
| 2023-05-31 21:30:59 -0500 | Rating Details | |
| 2023-05-31 21:28:33 -0500 | Rating Details | |
| 2023-05-31 21:18:43 -0500 | Rating Details | |
| 2023-05-31 20:55:46 -0500 | Rating Details | |
| 2023-05-31 20:44:37 -0500 | Rating Details | |
| 2023-05-31 20:28:56 -0500 | Rating Details | |
| 2023-05-31 20:14:02 -0500 | Rating Details | |
| 2023-05-31 20:06:45 -0500 | Rating Details | |
| 2023-05-31 20:05:38 -0500 | Rating Details | |
| 2023-05-31 19:46:47 -0500 | Rating Details | |
| 2023-05-31 19:42:23 -0500 | Rating Details | |
| 2023-06-02 13:35:21 -0500 | Rating Details | |
| 2023-06-02 11:37:48 -0500 | Rating Details | |
| 2023-06-02 09:24:18 -0500 | Rating Details | |
| 2023-06-02 02:43:48 -0500 | Rating Details | |
| 2023-06-01 22:55:07 -0500 | Rating Details | |
| 2023-06-01 20:46:16 -0500 | Rating Details | |
| 2023-06-01 19:50:24 -0500 | Rating Details | |
| 2023-06-03 09:01:11 -0500 | Rating Details | |
| 2023-06-03 08:39:13 -0500 | Rating Details | |
| 2023-06-03 08:02:00 -0500 | Rating Details | |
| 2023-06-03 07:36:56 -0500 | Rating Details | |
| 2023-06-03 07:21:52 -0500 | Rating Details | |
| 2023-06-03 06:17:24 -0500 | Rating Details | |
| 2023-06-03 06:07:02 -0500 | Rating Details | |
| 2023-06-03 05:39:31 -0500 | Rating Details | |
| 2023-06-03 02:25:47 -0500 | Rating Details | |
| 2023-06-03 01:18:53 -0500 | Rating Details | |
| 2023-06-03 00:57:12 -0500 | Rating Details | |
| 2023-06-01 17:37:45 -0500 | Rating Details | |
| 2023-06-14 11:59:30 -0500 | Rating Details | |
| 2023-08-12 08:31:12 -0500 | Rating Details |